If you prefer an oral solution and want clinical trialbacked evidence, a program like Motus may be a reasonable alternative to discuss with your clinician
Studies of GLP-1s show patients average weight loss ranges from 5% to 20% of their body weight
Phase 2 results (48 weeks): 1mg dose: 8.7% average weight loss 4mg dose: 17.1% average weight loss 8mg dose: 22.8% average weight loss 12mg dose: 24.2% average weight loss Placebo: 2.1% average weight loss These numbers came from a 48-week study period, six months shorter than the 72-week SURMOUNT trials
Side effects dont matter Expecting GLP-1 users to manage discomfort without targeted support is a flawed assumption
Mask R-CNN provides efficient and accurate measurement of chondrocyte viability in the label-free assessment of articular cartilage
Kurane, R., Suzuki, T., Fukuoka, S